COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of BufferGel in Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00000927
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : January 9, 2007
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:

The purpose of this study is to see if it is safe to use BufferGel in the vaginas of women who do not have HIV and who have a low risk of getting HIV.

Many new cases of HIV are the result of heterosexual activity. Condom use is currently the only effective way of preventing the spread of HIV and other sexually transmitted diseases (STDs). However, women, who have a greater risk of getting HIV, are often unable to convince their partner to use a condom. Therefore, it is important to develop methods that prevent the spread of HIV and that are controlled by the woman, such as medicines used in the vagina. BufferGel is known to kill the organisms that cause STDs, including HIV. BufferGel may do this without causing genital irritation and sores as other medicines do. More studies are needed to see if this is true.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: BufferGel Phase 1

Detailed Description:

Heterosexual transmission of HIV presently accounts for the vast majority of new HIV infections worldwide. Currently the condom is the only method available that has been shown to be effective against HIV and other sexually transmitted diseases (STDs). However, women who are at the greatest risk for acquiring HIV are often unable to negotiate condom use. Therefore, it is important that effective female-controlled barrier methods, such as topical microbicides, be made available to women. BufferGel has sufficient buffer capacity to acidify twice its own volume in human semen, which inactivates STD pathogens, including HIV. Unlike most other topical microbicides, BufferGel is non-detergent so it should not cause genital irritation and lesions. The safety and acceptability of BufferGel still need to be studied more carefully.

Participants are divided into two cohorts. Cohort IA consists of sexually abstinent women and cohort IB consists of sexually active women. Within each U.S. cohort, participants are assigned to apply BufferGel either once or twice daily. Within each international cohort, all participants apply BufferGel twice daily. Participants apply BufferGel for 14 days. Pelvic examinations are performed at Days 7 and 14.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Primary Purpose: Prevention
Official Title: Phase I Vaginal Microbicide Study of BufferGel

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

All participants must have:

  • HIV-negativity by licensed EIA.
  • Willingness and ability to complete a study diary.
  • A regular menstrual cycle with a minimum of 18 days between menses.
  • Ability to insert BufferGel daily as required by the protocol.

Cohort IA participants must:

  • Agree to abstain from sexual intercourse for the duration of the study.

Cohort IB participants must:

  • Agree to have vaginal intercourse at least 2 times per week and use non-lubricated condoms for each act of intercourse.
  • Have currently (for 3 months or longer) a single sexual partner who is at low-risk for HIV infection.

Exclusion Criteria

Co-existing Condition:

Participants with the following conditions or symptoms are excluded:

  • A Grade 3 or higher liver, renal, or hematology abnormality.
  • Menopausal.
  • Breakthrough menstrual bleeding.
  • Any STD or symptoms, as seen on pelvic exam, consistent with an STD or other genital tract infection or trauma including vaginitis, cervicitis, edema, erythema, ecchymosis, petechial hemorrhage, vulvar or cervicovaginal lesions or abrasions, subepithelial hemorrhage, or signs of genital tract infection (other than asymptomatic bacterial vaginosis) from laboratory evaluations.

Concurrent Medication:


  • Any vaginal product other than BufferGel, including lubricants and feminine hygiene products.
  • Vaginal drying agents.
  • Douche.
  • Participation in any other microbicide or contraceptive study.
  • Treatment for any STD.

Participants with the following prior conditions are excluded:

  • IUD, abnormal PAP smear, pregnancy, abortion, or gynecologic surgery in the last 3 months.
  • Any of the following side effects related to Depo-provera use in the past 2 months:
  • headaches, dizziness, abdominal pain, fatigue, or nervousness.

Prior Medication:


  • A course of antibiotic therapy (other than treatment for malaria) in the last 14 days.
  • Any spermicide within the past month.
  • Initiation of Depo-provera for contraceptive purposes in the last 6 months.

Risk Behavior:


  • Use of intravenous drugs currently or within the past year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00000927

Layout table for location information
United States, Rhode Island
Mem Hosp of Rhode Island
Pawtucket, Rhode Island, United States, 02860
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Layout table for investigator information
Study Chair: Kenneth Mayer
Study Chair: Kenrad Nelson
Layout table for additonal information Identifier: NCT00000927    
Other Study ID Numbers: HIVNET 009
First Posted: August 31, 2001    Key Record Dates
Last Update Posted: January 9, 2007
Last Verified: March 1999
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Administration, Topical
Mucous Membrane
Anti-Infective Agents
Cervix Uteri
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases